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Acinetobacter baumannii is an increasingly common nosocomial pathogen distributed worldwide (17, 28) . Infections caused by A. baumannii are associated with adverse clinical outcomes, including high rates of morbidity and mortality, prolonged hospital stay, and substantial health care expenses (3, 4, 15, 19, 28) . Over the past decade, increasingly resistant strains of multi-drug resistant A. baumannii (MDR-AB) have emerged. The prevalence of strains resistant to the usually potent and safe β-lactam antibiotics, such as ampicillin-sulbactam and carbapenems had increased substantially (5, 11, 12, 23) . Infection with MDR-AB is associated with even worse outcomes compared to infections due to non-MDR-AB (9, 27) . Of particular concern, strains of MDR-AB are now being encountered that are resistant to all commonly used antibiotics, including tigecycline and colistin (20).
The Detroit Medical Center (DMC) health system consist of 8 hospitals, has over 2,000 beds, and serves as a tertiary referral hospital for the metropolitan Detroit area and southeastern Michigan. A. baumannii has been a prominent pathogen in southeastern Michigan for several years (13) . The objectives of this study were to conduct a retrospective analysis of the trends in prevalence, resistance, and clonality, among clinical isolates of A. baumannii at DMC, with a particular focus on the emergence of strains resistant to all available treatment options.
The DMC has a single centralized Clinical Microbiology Laboratory, which process ~500,000 samples annually. A. baumannii was recovered from samples by using tigecycline and colistin were 4 µg/ml and 8 µg/ml, and 0.5 µg/ml and 1 µg/ml, respectively. A notable exception to the overall trend of reduced susceptibility to antibiotics during the study period was tobramycin -susceptibility increased from 41% to 65% during the study period. One isolate was resistant to all antimicrobials, including tobramycin.
Twenty-seven MDR-AB isolates from our health system in 2007-8 were genotyped using PFGE and REP-PCR. Results obtained using the PFGE genotyping and REP-PCR methods were completely concordant. As displayed in Figures 1 and 2 , characteristic of the surge in MDR-AB at our health system was polyclonal in nature.
More than 80% of the isolates analyzed clustered into 2 major clones as displayed in figure 1; 10 (38%) belonged to cluster I and 12 to cluster II (46%). The remaining isolates belonged to three different clusters: 1 to cluster III (4%), 2 to cluster IV (8%), and 1 to cluster V (4%).
This report describes a multi-institutional epidemic of MDR-AB at the DMC. (8, 16, 21) . Colistin is an old antimicrobial agent, which has not undergone rigorous pharmacokinetic and pharmacodynamic study. Therefore, strategies to maximize its efficacy and minimize its known renal and neurological toxicities remain unclear and need to be developed. Tigecycline, a glycylcycline, is a relatively new agent and is one of the few remaining options for the treatment of MDR-AB. It has a relatively safe therapeutic profile, but since greater than 80% of isolates at DMC in 2008 were nonsusceptible, as determined by E test (MIC≥4 µg/ml), its therapeutic utility appears limited. Recent studies comparing the E-test with the broth microdilution (BMD) method, have reported major discordances in in-vitro susceptibility results, with E test often reporting much higher MICs (7, 22) The genotypic distribution of MDR-AB strains in DMC, as in other parts of the world, displayed polyclonal characteristics (14, 18) . This highlights a relative discrepancy between the clinical manifestation of "classic" outbreaks, where a single clone is spread from patient-to patient in a given location and time, and polyclonal outbreaks, where genotypically distinct strains contribute to outbreaks. This discrepancy may be attributed to the spread of a mobile genetic element among A. baumannii isolates although we could not investigate the presence of a mobile genetic element in this study (18) . It should be emphasize though, that strains were collected for further molecular analysis by the microbiology laboratory upon request by infection control. These requests occurred only in the last 2 years of the study, when the surge in MDR-AB incidence was appreciated. The lack of availability of strains from our health system for genotypic comparison to more recent isolates is a weakness of the study. 
